Zogenix to Develop and Commercialize Proprietary Long-Acting Risperidone Formulation for Needle-Free Subcutaneous Administration Using the DosePro Delivery System and DURECT's SABER Depot Technology

Zogenix, Inc. ZGNX and DURECT Corporation DRRX announced today a development and license agreement. Under the agreement, Zogenix will be responsible for the clinical development and commercialization of a proprietary, long-acting injectable formulation of risperidone using DURECT's SABE controlled-release formulation technology in combination with Zogenix's DosePro needle-free, subcutaneous drug delivery system.   The Companies will also share non-clinical development responsibilities. Zogenix expects to initiate clinical studies for the new product candidate, Relday, in patients with schizophrenia in early 2012 following filing of an Investigational New Drug application.